BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact with the other FGFRs used for the treatment of metastatic bladder cancer (urothelial cell carcinoma) and achondroplasia (dwarfism). BioClin conducts clinical studies including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, and also with pembrolizumab, an immune checkpoint inhibitor in patients with metastatic urothelial cell carcinoma and other solid tumors. BioClin is headquartered in San Leandro, California, the US.

BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
BioClin Therapeutics Raises Additional USD20 Million in Series B Financing 9
BioClin Therapeutics Raises USD30 Million in Series B Financing 11
BioClin Therapeutics Secures USD13 Million in Series A Round of Funding 13
BioClin Therapeutics Raises US$6 Million In Venture Financing 14
BioClin Therapeutics Raises USD10 Million in Venture Financing 15
BioClin Therapeutics Inc - Key Competitors 16
BioClin Therapeutics Inc - Key Employees 17
BioClin Therapeutics Inc - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 18, 2018: Bioclin Therapeutics announces new leadership to advance late-stage bladder cancer development program 19
Jun 26, 2018: BioClin Therapeutics Names Scott Myers as Chairman to its Board of Directors 20
Jan 09, 2018: BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer 21
Product News 22
05/17/2018: BioClin Therapeutics Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 22
01/09/2018: BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List Of Tables


BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
BioClin Therapeutics Raises Additional USD20 Million in Series B Financing 9
BioClin Therapeutics Raises USD30 Million in Series B Financing 11
BioClin Therapeutics Secures USD13 Million in Series A Round of Funding 13
BioClin Therapeutics Raises US$6 Million In Venture Financing 14
BioClin Therapeutics Raises USD10 Million in Venture Financing 15
BioClin Therapeutics Inc, Key Competitors 16
BioClin Therapeutics Inc, Key Employees 17

List Of Figures


Xinjiang Goldwind Science & Technology Co Ltd, Performance Chart (2013 - 2017) 31
Xinjiang Goldwind Science & Technology Co Ltd, Ratio Charts 33
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals By Year, 2012 to YTD 2018 34
Xinjiang Goldwind Science & Technology Co Ltd, Power, Deals by Type, 2012 to YTD 2018 35

BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity

USD 250 View Report

BioClin Therapeutics Inc - Pharmaceuticals and Healthcare - Deals and Alliances Profile

BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity

USD 250 View Report

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review

Gene Biotherapeutics Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Torque Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Torque Therapeutics Inc (Torque) is an immuno-oncology company focused on developing first-in-class deep primed T Cell therapeutics to cure cancer. Its product pipeline includes Deep IL-15 used for for hematologic

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available